uS17, uS9 (S16) and uS13 (S18) have been also identified as putative biomarkers for response to Topoisomerase II (TOP2) in the treatment of glioblastoma, the most malignant brain tumor in adults. The gene discussed is TOP2A; the disease is glioblastoma.